Biogen Expands Gene Therapy Efforts Via Deals With Regenxbio, Penn
This article was originally published in The Pink Sheet Daily
Executive Summary
Biotech gets AAV technology license from Regenx for use in developing therapeutics for rare genetic eye disorders, which will be developed in tandem with University of Pennsylvania researchers.
You may also be interested in...
Biopharma Quarterly Dealmaking Statistics, Q2 2016
Biopharma financing decreased by 16% in Q2 to $4.8 billion, while the total value of acquisitions nearly doubled to $22 billion, including AbbVie's $9.8 billion takeover of Stemcentrx. Alliances garnered an aggregate potential deal value of $23.1 billion, led by Allergan's CNS agreement with Heptares.
Spotlight Returns To Biogen R&D To Sustain Success
After an impressive commercial run for Biogen Idec, with four drug launches in two years, it’s up to R&D to deliver more innovative medicines. The bar is high in the areas of neurology Biogen is exploring; Chief Medical Officer Alfred Sandrock discussed the company’s R&D momentum in a recent interview.
‘Green’ Beauty No Better Than Mainstream At Avoiding PFAS Contamination – Mamavation Study
Women’s wellness website and activist campaign Mamavation says its findings weren’t unexpected per se, “but we were surprised at the amount of contamination we discovered.” So why are mainstream and green beauty brands alike being contaminated with PFAS “forever chemicals”?